Skip to main content
SpringerLink
Log in

Coronary Artery Disease in HIV-Infected Patients: Clinical Presentation, Pathophysiology, Prognosis, Prevention, and Treatment

  • Chapter
Cardiovascular Disease in AIDS

  • 296 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klein D, Hurley LB, Quesenberry CP J, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Synd 30:471–477

    CAS  Google Scholar 

  2. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17:2479–2486

    PubMed  Google Scholar 

  3. Friis-Moller N, Sabin CA, Weber R, et al (2003) Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003

    PubMed  Google Scholar 

  4. Holmberg SD, Hamburger ME, Moorman AC et al (2002) HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748

    Article  PubMed  CAS  Google Scholar 

  5. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702–710

    PubMed  CAS  Google Scholar 

  6. Henry K, Melroe H, Huebsch J et al (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328

    PubMed  CAS  Google Scholar 

  7. Berhens G, Schmidt H, Meyer D, Stoll M, Schmidt RE (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958

    Google Scholar 

  8. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958–1959

    Article  PubMed  CAS  Google Scholar 

  9. Vittecoq D, Escaut L, Monsuez JJ (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1959

    Article  PubMed  CAS  Google Scholar 

  10. Jutte A, Schwenk A, Franzen C et al (1999) Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 13:1796–1797

    Article  PubMed  CAS  Google Scholar 

  11. Rickerts V, Brodt H-R, Staszewski S, Stille W (2000) Incidence of myocardial infarction in HIV-infected patients between 1983 and 1998: the Frankfurt HIVcohort study. Eur J Med Res 5:329–333

    PubMed  CAS  Google Scholar 

  12. Duong M, Cottin Y, Piroth L et al (2002) Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 34:523–528

    Article  PubMed  CAS  Google Scholar 

  13. Boccara F, Adda N, Rozenbaum W, Cohen A (2002) Acute coronary syndrome in HIV-infected patients. European Society of Cardiology, Berlin, September 2002. Europ Heart J vol 4, Abstr. Suppl. August 2002, abstract no. 3000, p 585

    Google Scholar 

  14. Barbaro G, Di Lorenzo G, Cirelli A et al (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25:2405–2418

    Article  PubMed  CAS  Google Scholar 

  15. Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004) Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23:625–630

    Article  PubMed  CAS  Google Scholar 

  16. Neumann T, Woiwod T, Neumann A et al (2004) Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients & part III: age differences. Eur J Med Res 9:267–272

    PubMed  Google Scholar 

  17. Hadigan C, Meigs JB, Wilson PW et al (2003) Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 36:909–916

    Article  PubMed  Google Scholar 

  18. Saves M, Chene G, Ducimetiere P et al (2003) French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37:292–298

    PubMed  Google Scholar 

  19. Doughty M, Mehta R, Bruckman D et al (2002) Acute myocardial infarction in the young — The University of Michigan experience. Am Heart J 143:56–62

    Article  PubMed  Google Scholar 

  20. Akosah KO, Cerniglia RM, Havlik P et al (2001) Myocardial infarction in young adults with low-density lipoprotein cholesterol levels < or = 100 mg/dL: clinical profile and 1-year outcomes. Chest 120:1953–1958

    Article  PubMed  CAS  Google Scholar 

  21. Fournier JA, Sanchez-Gonzalez A, Quero J et al (1997) Normal angiogram after myocardial infarction in young patients: a prospective clinical angiographic and long-term follow-up study. Int J Cardiol 60:281–287

    Article  PubMed  CAS  Google Scholar 

  22. Boccara F, Teiger E, Cohen A (2002) Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors. J Invasive Cardiol 14:343–346

    PubMed  Google Scholar 

  23. d’Arminio A, Sabin CA, Phillis AN et al (2004) Writing Committee of the DAD Study Group. Cardio-and cerebrovascular events in HIV-infected persons. AIDS 18:1811–1817

    PubMed  CAS  Google Scholar 

  24. Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrohy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51–8

    Article  PubMed  CAS  Google Scholar 

  25. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 352:1881–1883

    Article  Google Scholar 

  26. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093–2099

    PubMed  CAS  Google Scholar 

  27. Piériard D, Telenti A, Sudre P et al (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100:700–705

    Google Scholar 

  28. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al (2002) NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569–577

    Article  PubMed  CAS  Google Scholar 

  29. Dube MP, Stein JH, Aberg JA et al (2003) Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37:613–627

    PubMed  Google Scholar 

  30. Stein JH, Merwood MA, Bellehumeur JL et al (2004) Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 147:713

    CAS  Google Scholar 

  31. Toth PP (2004) High-density lipoprotein and cardiovascular risk. Circulation 109:1809–1812

    Article  PubMed  Google Scholar 

  32. Shah PK, Amin J (1992) Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85:1279–1285

    PubMed  CAS  Google Scholar 

  33. Khan NA, Di Cello F, Nath A, Kim KS (2003) Human immunodeficiency virus type 1 Tat-mediated cytotoxicity of human brain microvascular endothelial cells. J Neurovirol 9:584–593

    PubMed  CAS  Google Scholar 

  34. Schecter AD, Berman AB, Yi L, Mosoian A et al (2001) HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci 98:10142–10147

    Article  PubMed  CAS  Google Scholar 

  35. Barbaro G (2002) Cardiovascular manifestations of HIV infection. Circulation 106:1420–1425

    Article  PubMed  Google Scholar 

  36. de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA (2003) Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 14:15–18

    PubMed  Google Scholar 

  37. Stins MF, Pearce D, Di Cello F, Erdreich-Epstein A, Pardo CA, Sik Kim K (2003) Induction of intercellular adhesion molecule-1 on human brain endothelial cells by HIV-1 gp120: role of CD4 and chemokine coreceptors. Lab Invest 83:1787–1798

    Article  PubMed  CAS  Google Scholar 

  38. Stein JH, Klein MA, Bellehumeur JL et al (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257–262

    PubMed  CAS  Google Scholar 

  39. Hulgan T, Morrow J, D’Aquila RT et al (2003) Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 37:1711–1717

    Article  PubMed  CAS  Google Scholar 

  40. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R (2004) HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 4:213–222

    PubMed  Google Scholar 

  41. Wu RF, Gu Y, Xu YC, Mitola S, Bussolino F, Terada LS (2004) Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoskeletal dynamics through PAK1 activation and oxidant production. J Virol 78:779–789

    PubMed  CAS  Google Scholar 

  42. Paladugu R, Fu W, Conklin BS et al (2003) HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 38:549–555

    Article  PubMed  Google Scholar 

  43. Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev 1:329–337

    PubMed  CAS  Google Scholar 

  44. Karmochkine M, Ankri A, Calvez V, Bonmarchant M, Coutellier A, Herson S (1998) Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 80:208–209

    PubMed  CAS  Google Scholar 

  45. Escaut L, Monsuez JJ, Chironi G et al (2003) Coronary artery disease in HIV infected patients. Intensive Care Med 29:969–973

    PubMed  Google Scholar 

  46. David MH, Hornung R, Fichtenbaum CJ (2002) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 34:98–102

    Article  PubMed  Google Scholar 

  47. Barbaro G, Barbarini G, Pellicelli AM (2001) HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 344:1799–1800

    Article  PubMed  CAS  Google Scholar 

  48. Tabib A, Leroux C, Mornex JF, Loire R (2000) Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 11:41–46

    Article  PubMed  CAS  Google Scholar 

  49. Hsue PY, Lo JC, Franklin A et al (2004) Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109:1603–1608

    PubMed  Google Scholar 

  50. Mercie P, Thiebaut R, Lavignolle V et al (2002) Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 34:55–63

    Article  PubMed  Google Scholar 

  51. Depairon M, Chessex S, Sudre P et al (2001) Premature atherosclerosis in HIV-infected individuals — focus on protease inhibitor therapy. AIDS 15:329–334

    PubMed  CAS  Google Scholar 

  52. Maggi P, Serio G, Epifani G et al (2000) Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14:F123–128

    PubMed  CAS  Google Scholar 

  53. Seminari E, Pan A, Voltini G et al (2002) Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162:433–438

    Article  PubMed  CAS  Google Scholar 

  54. Acevedo M, Sprecher DL, Calabrese L et al (2002) Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: a call for cardiovascular prevention. Atherosclerosis 163:349–354

    Article  PubMed  CAS  Google Scholar 

  55. Talwani R, Falusi OM, Mendes de Leon CF et al (2002) Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr 30:191–195

    PubMed  Google Scholar 

  56. Meng Q, Lima JA, Lai H et al (2002) Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 144:642–648

    PubMed  Google Scholar 

  57. Matetzky S, Domingo M, Kar S et al (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163:457–460

    PubMed  Google Scholar 

  58. Hsue PY, Giri K, Erickson S et al (2004) Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109:316–319

    PubMed  Google Scholar 

  59. Ambrose JA, Gould RB, Kurian DC et al (2003) Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection. Am J Cardiol 92:301–303

    Article  PubMed  Google Scholar 

  60. Varriale P, Saravi G, Hernandez E, Carbon F (2004) Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 147:55–59

    Article  PubMed  CAS  Google Scholar 

  61. Boccara F, Odi G, Teiger E, Di Angelantonio E, Cohen A, Barbarini G, Barbaro G, on behalf the French Italian Study on Coronary artery disease in AIDS patients (2004) Coronary revascularization in HIV-infected patients with coronary artery disease: a multicenter case-control study. 11th CROI (Conference on Retrovirus and Opportunistic Infections), Feb 2004, San Francisco, USA, poster no. 740

    Google Scholar 

  62. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180–187

    PubMed  Google Scholar 

  63. Lauer MS (2002) Aspirin for primary prevention of coronay events. N Engl J Med 346:1468–1474

    Article  PubMed  Google Scholar 

  64. Preventive services task force (2002) Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136:157–160

    Google Scholar 

  65. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K (1998) Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140:199–270

    Article  PubMed  CAS  Google Scholar 

  66. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 285:2486–2497

    Google Scholar 

  67. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569–577

    Article  PubMed  CAS  Google Scholar 

  68. de Luis DA, Bachiller P, Aller R, Eiros Bouza J, Izaola O (2003) Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report. Nutrition 19:903–904

    PubMed  Google Scholar 

  69. Benesic A, Zilly M, Kluge F et al (2004) Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 32:229–333

    Article  PubMed  CAS  Google Scholar 

  70. Palacios R, Santos J, Gonzalez M et al (2002) Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 30:536–537

    PubMed  CAS  Google Scholar 

  71. Calza L, Manfredi R, Chiodo F (2002) Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30:26–31

    Article  PubMed  CAS  Google Scholar 

  72. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J (1998) Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352:1031–1032

    PubMed  CAS  Google Scholar 

  73. Thomas JC, Lopes-Virella MF, Del Bene VE et al (2000) Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy 20:727–734

    PubMed  CAS  Google Scholar 

  74. Van der Valk M, Kastelein JJ, Murphy RL et al (2001) Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15:2407–2414

    PubMed  Google Scholar 

  75. Negredo E, Ribalta J, Paredes R et al (2002) Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16:1383–1389

    Article  PubMed  CAS  Google Scholar 

  76. Bonnet F, Bonarek M, De Witte S, Beylot J, Morlat P (2002) Efavirenz-associated severe hyperlipidemia. Clin Infect Dis 3:776–777

    Google Scholar 

  77. Murphy RL, Smith WJ (2002) Switch studies: a review. HIV Med 3:146–155

    Article  PubMed  CAS  Google Scholar 

  78. Domingo P, Labarga P, Palacios R et al (2004) RECOVER Study Group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 18:1475–1478

    PubMed  Google Scholar 

  79. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB (2000) Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis 31:808–812

    Article  PubMed  CAS  Google Scholar 

  80. Stall RD, Greenwood GL, Acree M, Paul J, Coates TJ (1999) Cigarette smoking among gay and bisexual men. Am J Public Health 89:1875–1878

    Google Scholar 

  81. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK (2002) Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis 186:1023–1027

    Article  PubMed  Google Scholar 

  82. The Writing Group for the Activity Counseling Trial Research Group (2001) Effects of physical activity counseling in primary care: the Activity Counseling Trial: a randomized controlled trial. JAMA 286:677–687

    Article  Google Scholar 

  83. Stewart KJ (2002) Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 288:1622–1631

    Article  PubMed  Google Scholar 

  84. Roubenoff R, Schmitz H, Bairos L et al (2002) Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 34:390–393

    Article  PubMed  Google Scholar 

  85. Moyle G, Baldwin C, Phillpot M (2001) Managing metabolic disturbances and lipodystrophy: diet, exercise, and smoking advice. AIDS Read 11:589–592

    PubMed  CAS  Google Scholar 

  86. Thoni GJ, Fedou C, Brun JF et al (2002) Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 28:397–404

    PubMed  CAS  Google Scholar 

  87. Barbaro G, Fisher SD, Lipshultz SE (2001) Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 1:115–124

    PubMed  CAS  Google Scholar 

  88. Lewis W (2001) AIDS cardiomyopathy: physiological, molecular, and biochemical studies in the transgenic mouse. Ann N Y Acad Sci 946:46–56

    PubMed  CAS  Google Scholar 

  89. Nakai K, Itoh C, Nakai K, Habano W, Gurwitz D (2001) Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. Am J Cardiovasc Drugs 1:353–361

    PubMed  CAS  Google Scholar 

  90. Vilaseca MA, Sierra C, Colome C et al (2001) Hyperhomocysteinaemia and folate deficiency in human immunodeficiency virus-infected children. Eur J Clin Invest 31:992–998

    Article  PubMed  CAS  Google Scholar 

  91. Cohn JE (2001) Homocysteine, HIV, and heart disease. AIDS Treat News 370:5–6

    PubMed  Google Scholar 

  92. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A (2001) Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 15:1081–1082

    Article  PubMed  CAS  Google Scholar 

  93. Dube MP (2003) Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 31:1467–1475

    Google Scholar 

  94. Walli R, Herfort O, Michl GM et al (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12:F167–173

    PubMed  CAS  Google Scholar 

  95. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J (2004) Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 9:161–177

    PubMed  CAS  Google Scholar 

  96. Henry P, Thomas F, Benetos A, Guize L (2002) Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 40:458–463

    Article  PubMed  CAS  Google Scholar 

  97. Hadigan C, Rabe J, Grinspoon S (2002) Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virusinfected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 87:4611–4615

    Article  PubMed  CAS  Google Scholar 

  98. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284:472–477

    Article  PubMed  CAS  Google Scholar 

  99. Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350:1220–1234

    Article  PubMed  CAS  Google Scholar 

  100. Yki-Jarvinen H, Sutinen J, Silveira A et al (2003) Regulation of plasma PAI-1 concentrations in HAART associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 23:688–694

    PubMed  Google Scholar 

  101. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S (2004) Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 140:786–794

    PubMed  CAS  Google Scholar 

  102. Sattler FR, Qian D, Louie S et al (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15:2001–2010

    Article  PubMed  CAS  Google Scholar 

  103. Jung O, Bickel M, Ditting T et al (2004) Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 19:2250–2258

    PubMed  Google Scholar 

  104. Chobanian AV, Bakris GL, Black HR et al (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572

    Article  PubMed  CAS  Google Scholar 

  105. Braunwald E, Antman EM, Beasley JW et al (2002) ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction-2002: summary article: A Report of the American College of Cardiology/American Heart Association Task Force On Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106:1893–1900

    PubMed  Google Scholar 

  106. Hamm CW, Bertrand M, Braunwald E (2001) Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 358:1533–1538

    Article  PubMed  CAS  Google Scholar 

  107. Antman EM, Anbe DT, Armstrong PW et al (2004) American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–292

    Article  PubMed  Google Scholar 

  108. Volberding PA, Murphy RL, Barbaro G et al (2003) The Pavia consensus statement. AIDS 17[Suppl 1]:S170–179

    PubMed  Google Scholar 

  109. Trachiotis GD, Alexander EP, Benator D, Gharagozloo F (2003) Cardiac surgery in patients infected with the human immunodeficiency virus. Ann Thorac Surg 76:1114–1118

    Article  PubMed  Google Scholar 

  110. Halpern SD, Ubel PA, Caplan AL (2002) Solid-organ transplantation in HIV-infected patients. N Engl J Med 347:284–287

    Article  PubMed  Google Scholar 

  111. Morgan JA, Bisleri G, Mancini DM (2003) Cardiac transplantation in an HIV-1-infected patient. N Engl J Med 349:1388–1389

    Article  PubMed  CAS  Google Scholar 

  112. Bisleri G, Morgan JA, Deng MC, Mancini DM, Oz MC (2003) Should HIV-positive recipients undergo heart transplantation? J Thorac Cardiovasc Surg 126:1639–1640

    Article  PubMed  Google Scholar 

Download references

Authors
  1. F. Boccara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Pathophysiology, University “La Sapienza”, Rome, Italy

    Giuseppe Barbaro

  2. Department of Cardiology, Saint Antoine University Hospital, Assistance Publique - Hôpitaux de Paris and Université Paris VI, Paris, France

    Franck Boccara

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Italia

About this chapter

Cite this chapter

Boccara, F., Cohen, A. (2005). Coronary Artery Disease in HIV-Infected Patients: Clinical Presentation, Pathophysiology, Prognosis, Prevention, and Treatment. In: Barbaro, G., Boccara, F. (eds) Cardiovascular Disease in AIDS. Springer, Milano. https://doi.org/10.1007/88-470-0358-X_6

Download citation

  • DOI: https://doi.org/10.1007/88-470-0358-X_6

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0309-5

  • Online ISBN: 978-88-470-0358-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation